AAM Calls for Increased Voluntary Licensing of Covid Vaccines to Increase Patient Access
WASHINGTON, D.C. (August 16, 2021) — AAM and its member companies have worked extremely hard to enhance patient access to affordable treatments throughout the COVID-19 pandemic. This includes manufacturing dexamethasone, which is estimated to have saved more than 1 million lives worldwide, and producing under voluntary licensing agreements leading vaccines and other therapeutics for use […]
U.S. v. Arthrex
On December 2, 2020 AAM filed a brief in the Supreme Court in U.S. v. Arthrex, the latest constitutional challenge to IPR – urging the Court to uphold the system. Among other things, the brief explains how IPR is a necessary tool to combat pharmaceutical patent abuse. View Brief
AAM Amicus Brief – Oil States
A speedy and efficient mechanism to challenge improvidently granted patents is essential to the timely provision of generic and biosimilar medicines. The availability of generic and biosimilar medicines saves money and provides greater patient access to critical medicines. See our amicus brief on how the Inter partes review is essential to the limited regulatory objective […]
TC HEARTLAND, LLC D/B/A HEARTLAND FOOD PRODUCTS GROUP v. KRAFT FOODS GROUP BRANDS LLC
In an amicus brief filed with the United States Supreme Court, AAM explained that the Federal Circuit had misinterpreted the law governing where Hatch-Waxman patent lawsuits can be filed resulting in an imbalance that favored the brand industry and delayed patient access to lower-cost generic drugs. On May 22, 2017, the Supreme Court agreed with […]
SAINT REGIS MOHAWK TRIBE and ALLERGAN, INC. v. MYLAN PHARMACEUTICALS, INC ., TEVA PHARMACEUTICALS USA, INC., and AKORN, INC.
Friday the Association for Accessible Medicines filed an amicus brief in the U.S. Court of Appeals for the Federal Circuit calling on the court to reject gamesmanship of the patent system which keeps prescription drug prices high for patients. In this case, Allergan Inc. has transferred its patents to the St. Regis Mohawk Native American […]
MOMENTA PHARMACEUTICALS, INC. v. BRISTOL-MYERS SQUIBB COMPANY
In an amicus brief submitted to the United States Court of Appeals for the Federal Circuit, AAM urged the Court to reject an interpretation of the law that would have prevented biosimilar developers from utilizing the Inter Partes Review (IPR) process at the U.S. Patent and Trade Office—a process designed to weed out invalid patents […]
AAM Amicus Brief – Mylan vs. Allergan
Generic drug and biosimilar companies support innovation in medicine to benefit patients. Brand name drug companies who abuse the patent system harm patients. See our amicus brief opposing the rental of Native American tribal sovereign immunity by a brand name pharmaceutical company to extend its drug patent monopoly and keep prices high. View Brief
AAM SUPPORTING PETITIONERS ON SEVERABILITY
On May 14, 2020 The Association for Accessible Medicines (AAM) filed an amicus brief in the latest constitutional challenge to the Affordable Care Act (ACA), arguing for the survival of biosimilars pathway (BPCIA), even if the individual mandate of the ACA is found unconstitutional. View Brief
Competition Matters. That’s Why We Need to Further Improve IPR.
Inter Partes Review (IPR) is a process that allows patent experts to take a second look at patents and ensure that every granted patent represents true innovation. This graphic demonstrates how IPR improves patent quality, accelerates competition and makes lower-cost generics and biosimilars accessible to U.S. patients. Market circumstances make this measure necessary. Brand-name pharmaceutical […]
PFIZER, INC. v. JOHNSON & JOHNSON and JANSSEN BIOTECH, INC.
In an amicus brief filed in the United States District Court for the Eastern District of Pennsylvania, AAM urged the Court to reject exclusionary contracting and bundling practices that threaten to foreclose or delay biosimilar competition. AAM’s brief helped to explain the need for robust biosimilar competition, the costs and burdens of developing biosimilars, and […]
AAM Files Amicus Brief in Helsinn v Teva
WASHINGTON, DC (October 17, 2018)–Yesterday the Association for Accessible Medicines (AAM) filed an amicus brief in the Supreme Court case Helsinn v. Teva calling on the court to reject one form of patent system manipulation attempted by a brand-name drug company. The case will be heard on December 4. For nearly two hundred years, the […]
AAM Statement on PACED Act of 2018
MEDIA ADVISORY “With everyone from patients to the president demanding action on drug pricing, AAM welcomes the introduction of the Preserving Access to Cost Effective Drugs (“PACED”) Act of 2018. This legislation will put a stop to the recent anticompetitive ploy made infamous by Allergan when it rented sovereign immunity from a Native American […]
